LENZ Therapeutics (LENZ) Accumulated Expenses (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Accumulated Expenses data on file, last reported at $14.9 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 203.12% year-over-year to $14.9 million in Q1 2026; TTM through Mar 2026 was $14.9 million, a 203.12% increase from a year earlier, with the FY2025 full-year figure at $17.0 million, up 176.79% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $14.9 million, down from $17.0 million in the prior quarter.
• Over the last five years, Accumulated Expenses for LENZ reached as high as $17.0 million in Q4 2025 and fell as low as $1.0 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $6.9 million across 5 years, with a median of $4.9 million in 2024.
• Across the five-year window, Accumulated Expenses jumped 615.25% in 2023 and tumbled 58.25% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $1.9 million in 2022, then soared by 584.29% to $12.8 million in 2023, then plunged by 51.97% to $6.1 million in 2024, then jumped by 176.79% to $17.0 million in 2025, then retreated by 12.59% to $14.9 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $14.9 million in Q1 2026, $17.0 million in Q4 2025, and $12.0 million in Q3 2025.